Despite significant improvements in life expectancy for individuals with cystic fibrosis
(CF) over the last two decades, CF continues to be a life-shortening disorder characterized
by progressive, obstructive lung disease associated with chronic airway infection,
inflammation, and parenchymal damage. Abnormal ion transport in the CF airways and
altered antimicrobial airway defenses result in persistent infections with pathogens
such as Pseudomonas aeruginosa. Although the progression of CF lung disease is impacted by many factors, P. aeruginosa infection is clearly associated with irreversible parenchymal damage and a sharper
decline in lung function. Earlier age at first infection with P. aeruginosa has been associated with a 2.6 times higher risk of death [
[1]
], and repeated isolation of P. aeruginosa, or colonization, continues to be a major predictor of morbidity and mortality in
people with CF.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Cystic FibrosisAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.Pediatr Pulmonol. 2002; 34: 91-100https://doi.org/10.1002/ppul.10127
Cystic Fibrosis Foundation Patient Registry. 2021 annual data report. Bethesda, Maryland.
- Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.Eur Respir J. 2000; 16: 749https://doi.org/10.1034/j.1399-3003.2000.16d30.x
- Cystic fibrosis foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial pseudomonas aeruginosa infection.Ann Am Thorac Soc. 2014; 11: 1640-1650https://doi.org/10.1513/AnnalsATS.201404-166OC
- Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis.Lancet Lond Engl. 1985; 1: 865https://doi.org/10.1016/s0140-6736(85)92222-6
- Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment.Lancet. 1991; 338: 725-726https://doi.org/10.1016/0140-6736(91)91446-2
- Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.Pediatr Pulmonol. 2012; 47: 125-134https://doi.org/10.1002/ppul.21525
- Impact of antibiotic eradication therapy of Pseudomonas aeruginosa on long term lung function in cystic fibrosis.J Cyst Fibros. 2022; (Published online August)S1569199322006452https://doi.org/10.1016/j.jcf.2022.08.007
- The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis.Pediatr Pulmonol. 2011; 46: 554-558https://doi.org/10.1002/ppul.21417
- The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers.Thorax. 2018; 73: 388-390https://doi.org/10.1136/thoraxjnl-2017-210473
Article info
Identification
Copyright
© 2023 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Impact of antibiotic eradication therapy of Pseudomonas aeruginosa on long term lung function in cystic fibrosisJournal of Cystic FibrosisVol. 22Issue 1
- PreviewCystic fibrosis is a life-limiting autosomal recessive disorder with highest prevalence in Europe, North America and Australia [1]. Around 30,000 individuals are affected in the United States and 45,000 in Europe [2]. Over the last few decades, the median age of survival has increased substantially due to optimised treatment of secondary effects of CFTR dysfunction such as airway infection [3].
- Full-Text
- Preview
